Results 81 to 90 of about 477,894 (133)

Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants. [PDF]

J Infect Dis, 2022
Smith RA, Wu VH, Song J, Raugi DN, Diallo Mbaye K, Seydi M, Gottlieb GS.   +6 more
europepmc   +1 more source

Dissolution Profiles of Immediate Release Products of Various Drugs in Biorelevant Bicarbonate Buffer: Comparison with Compendial Phosphate Buffer. [PDF]

Pharm Res
Okamoto N, Higashino M, Yamamoto H, Sugano K.   +3 more
europepmc   +1 more source

Effectiveness of dolutegravir-based regimens compared to raltegravir-, elvitegravir-, bictegravir, and darunavir-based regimens among older adults with HIV in the Veterans Aging Cohort Study (VACS). [PDF]

AIDS Res Ther
Yan L, Henegar CE, Marconi VC, Gordon KS, Hicks C, Vannappagari V, Justice AC, Aslan M.   +7 more
europepmc   +1 more source

Pharmacokinetics, the Immunological Impact, and the Effect on HIV Ex-Vivo Infectivity of Maraviroc, Raltegravir, and Lopinavir in Men Who Have Sex with Men Using Postexposure Prophylaxis. [PDF]

AIDS Res Hum Retroviruses, 2023
Leal L, Guardo AC, Bedoya LM, Rodríguez de Miguel C, Climent N, Rovira C, Beltrán M, Llach J, Alcamí J, Kashuba ADM, Gatell JM, Plana M, García F.   +12 more
europepmc   +1 more source

Integrase inhibitor drugs during pregnancy and congenital anomalies: A case/non-case study from the global pharmacovigilance database VigiBase®. [PDF]

Pharmacol Res Perspect
Saint-Lary L, Lacroix I, Leroy V, Sommet A.   +3 more
europepmc   +1 more source

HIV-1 Integrase T218I/S Polymorphisms Do Not Reduce HIV-1 Integrase Inhibitors' Phenotypic Susceptibility. [PDF]

AIDS Res Hum Retroviruses
Rodríguez-López ER, López P, Rodríguez Y, Sánchez R, Acevedo VS, Encarnación J, Tirado G, Ortiz-Sánchez C, Mesplède T, Rivera-Amill V.   +9 more
europepmc   +1 more source

Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States. [PDF]

N Engl J Med, 2022
Patel K, Huo Y, Jao J, Powis KM, Williams PL, Kacanek D, Yee LM, Chadwick EG, Shiau S, Jacobson DL, Brummel SS, Sultan-Beyer L, Kahlert CR, Zash R, Seage GR, Pediatric HIV/AIDS Cohort Study, Swiss Mother and Child HIV Cohort Study.   +16 more
europepmc   +1 more source

Neurocognitive profile in HIV subjects on INSTI-regimen- one year follow up: Is there room for optimism? [PDF]

PLoS One
Brkić-Jovanović N, Karaman M, Andrić V, Marić D, Brkić S, Bugarski-Ignjatović V.   +5 more
europepmc   +1 more source

GS143, an inhibitor of E3 ligase β-TrCP, reverses HIV-1 latency without activating T cells via unconventional activation of NFκB. [PDF]

PLoS Pathog
Sarkar S, Kobayashi Y, Russnak T, Shen J, Nahass RG, Dougherty JP, Gélinas C.   +6 more
europepmc   +1 more source

A Health Literate Patient-focused Approach to the Redesign of the Raltegravir (ISENTRESS) Pediatric Kit and Instructions for Use. [PDF]

Pediatr Infect Dis J, 2022
Mills A, Myers L, Raudenbush C, Vossen DA, Teppler H, Miteva YR, Seeley S, Homony B, Straus WL.   +8 more
europepmc   +1 more source